羥氯喹全球市場規模、佔有率、成長分析、最終用戶、分銷管道 - 2024-2031 年產業預測

Global Hydroxychloroquine Market Size, Share, Growth Analysis, By End-User(Hospitals, Specialty Clinics), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy) - Industry Forecast 2024-2031

出版日期: 2024年03月17日 | 出版商:

SkyQuest | 英文 184 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年羥氯喹的全球市場規模將達到9,500億美元，從2023年的1兆美元成長到2031年的1.53兆美元，預測期間（2024-2031年）複合年成長率為5.40%。

該市場旨在為患有這些疾病的患者提供有效的治療解決方案，以緩解症狀、控制疾病並提高生活品質。羥氯喹市場的主要驅動力之一是瘧疾、類風濕性關節炎和狼瘡等疾病的流行，這些疾病影響著世界上很大一部分人口，因此需要廣泛使用羥氯喹作為治療方法。此外，老年人口的不斷成長和自體免疫疾病的增加也導致對羥氯喹的需求增加。但市面上也存在多種阻礙因素。對與羥氯喹相關的安全性和潛在副作用（例如視網膜毒性和心律不整）的擔憂促使醫療保健專業人員和患者保持謹慎。此外，有關羥氯喹使用的監管限制和指南，特別是仿單標示外處方情況對市場擴張構成了挑戰。羥氯喹市場也面臨一些障礙，例如替代治療方案的可用性以及瘧疾高發生率地區出現抗藥性。儘管如此，全球羥氯喹市場的一個重要目的是為患有瘧疾、類風濕性關節炎、紅斑性狼瘡和其他自體免疫疾病的人提供有效的治療選擇。儘管面臨挑戰，但正在進行的研究、臨床試驗和合作仍有充足的機會，有可能推動羥氯喹市場的成長和發展。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

Sanofi（France）
Novartis（Switzerland）
Aurobindo Pharma（India）
Dr. Reddy's Laboratories（India）
Sun Pharmaceutical Industries（India）
Cipla（India）
Teva Pharmaceuticals（Israel）
Hikma Pharmaceuticals（UK）
Sandoz（Switzerland）
Mylan（US）
Apotex（Canada）
Ranbaxy Laboratories（India）
Torrent Pharmaceuticals（India）
Lupin Pharmaceuticals（India）
Zydus Cadila（India）
Aurobindo Pharma USA（US）
Novartis Pharmaceuticals Corporation（US）
Sun Pharmaceutical Industries USA（US）
Hikma Pharmaceuticals USA（US）
Sandoz Inc.（US）

簡介目錄

Product Code: SQMIG15E2346

Global hydroxychloroquine market size was valued at USD 0.95 trillion in 2022 and is poised to grow from USD 1.00 trillion in 2023 to USD 1.53 trillion by 2031, at a CAGR of 5.40% during the forecast period (2024-2031).

The objective of the market is to offer an efficient therapeutic solution for patients grappling with these ailments, providing symptom relief, disease management, and enhanced quality of life. One of the primary driving forces behind the hydroxychloroquine market is the prevalence of diseases like malaria, rheumatoid arthritis, and lupus, which affect a substantial portion of the global population, necessitating widespread utilization of hydroxychloroquine as a treatment approach. Furthermore, the increasing elderly population and the consequent rise in autoimmune disorders contribute to the growing demand for hydroxychloroquine. However, the market encounters various restraining factors. Concerns regarding safety and potential side effects linked to hydroxychloroquine, such as retinal toxicity and cardiac arrhythmias, have prompted caution among healthcare practitioners and patients alike. Additionally, regulatory constraints and guidelines concerning hydroxychloroquine usage, particularly in off-label prescribing scenarios, pose challenges to market expansion. The hydroxychloroquine market also confronts hurdles such as the availability of alternative treatment options and the emergence of drug resistance in malaria-prone regions. Nevertheless, the global hydroxychloroquine market serves the crucial purpose of delivering effective treatment choices for individuals with malaria, rheumatoid arthritis, lupus, and other autoimmune disorders. Despite the challenges, opportunities abound in ongoing research, clinical trials, and collaborations, which have the potential to drive growth and advancement within the hydroxychloroquine market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global hydroxychloroquine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hydroxychloroquine Market Segmental Analysis

The global hydroxychloroquine market is segmented based on end-user, distribution channel, and region. By end-user, the market is segmented into hospitals, specialty clinics, homecare, and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Hydroxychloroquine Market

The global demand for hydroxychloroquine as a treatment for malaria remained a significant driver of market growth. Malaria is a widespread infectious disease, particularly prevalent in regions like Sub-Saharan Africa and Southeast Asia. Hydroxychloroquine has long been recognized as an effective antimalarial medication, contributing to its widespread usage. The continued efforts to combat malaria and the persistent need for effective treatment options further fueled the demand for hydroxychloroquine in 2022.

Restraints in the Global Hydroxychloroquine Market

The hydroxychloroquine market encountered a notable challenge stemming from safety concerns and regulatory restrictions linked to its usage. Various studies and reports spotlighting potential side effects, such as retinal toxicity and cardiac arrhythmias, prompted caution among healthcare professionals and regulatory bodies. Consequently, restrictions were imposed on the off-label utilization of hydroxychloroquine, accompanied by heightened scrutiny of its safety profile.

Market Trends of the Global Hydroxychloroquine Market

A noteworthy trend observed in the hydroxychloroquine market was the investigation of combination therapies. Researchers and healthcare professionals delved into the potential synergies of hydroxychloroquine when paired with other medications or treatment approaches. The objective was to improve treatment outcomes, mitigate side effects, and optimize therapeutic effectiveness across a range of disease conditions.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Hydroxychloroquine Market by End-User

Market Overview
Hospitals
Specialty Clinics
Homecare
and Others

Global Hydroxychloroquine Market by Distribution Channel

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
and Others

Global Hydroxychloroquine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apotex (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ranbaxy Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis Pharmaceuticals Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals USA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments